Myriad Genetics Inc (Myriad) is a molecular diagnostic testing company. It develops and offers molecular tests that assess the risk of developing diseases, guide treatment decisions, and provide insights across various medical specialties. The company serves industries such as oncology, women's health, and pharmacogenomics. Myriad also offers financial assistance and flexible payment plans. It also engages in biopharma services, offering companion diagnostic development and clinical trial testing.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Myriad is focused on the advancement of advancing its research and development (R&D) initiatives through a comprehensive approach to innovation. The company's R&D strategy focuses on expanding diagnostic capabilities, driving clinical utility, fostering strategic partnerships, and strengthening its intellectual property portfolio. The company invests in the development of new innovative testing products and the enhancement of its existing portfolio of testing products to enhance patient outcomes and broaden the accessibility of precision medicine. R&D efforts prioritize robust clinical data and assay development to address key clinical questions. By collaborating with healthcare professionals and researchers, the company strives to validate and improve the clinical efficacy of its diagnostic solutions. As part of its long-term growth strategy, the company plans to increase its investment in R&D in FY2026 to drive innovation and new product development and enhance clinical evidence generation through clinical studies. These initiatives align with the company's commitment to improving diagnostic accuracy, expanding its test portfolio, and strengthening its position in precision medicine. The R&D unit of Myriad is located at the Walter Gilbert Research and Innovation Center in South San Francisco, California, the US, which focuses on administration, R&D, and operates a laboratory for the company's Women’s Health business. In 2025, significant advancements were made in R&D efforts, strengthening the portfolio of innovative diagnostic solutions, including advancements in Molecular Residual Disease (MRD), Prenatal and Reproductive Health, Oncology and Companion Diagnostics, Hereditary Cancer and Preventive Genomics, and Prostate Cancer and Artificial Intelligence Development. Myriad Genetics received six new US patents in 2025 related to its high-definition, tumor-informed molecular residual disease (MRD) assay, Precise MRD. The company announced a collaboration with SOPHiA GENETICS SA to co-develop a global liquid biopsy companion diagnostic (CDx) testing solution. Additionally, the company advanced the development of an AI-enabled prostate cancer diagnostic test in collaboration with PATHOMIQ Inc. In FY2025, the company spent US$106.8 million on its R&D activities, which as a percentage of revenue, stood at 12.9%.